Siemens进入诊断检查市场站

体外和分子诊断市场正在快速增长，在大胆推进在该医疗解决方案市场中的地位，Siemens AG已经同意购买两家重要的诊断公司。

　　在获得Schering by BayerAG(Leverkusen, Germany)公司的认可之后，Siemens同意以42亿欧元购得Bayer医疗保健公司的诊断学分部。并购已经得到了Bayer监事会的批准，该方案涵盖了对许多疾病进行评估和监测的体外诊断产品，是一项庞大的投资组合。同样在该方案中，包括了硬件、信息技术(IT)网络、和复杂设备服务。Bayer公司糖尿病诊断部和Schering的诊断影像部则不包括在内。

　　Siemens Stages Entry as New Diagnostics Powerhouse

　　In a bold push to expand the position of its Medical Solutions group in the fast-growing in vitro and molecular diagnostics markets, Siemens AG has agreed to acquire two major diagnostic companies.

　　Following hard on the news of the acquisition of Schering by BayerAG (Leverkusen, Germany), Siemens agreed to acquire the Diagnostics Division of Bayer HealthCare for €4.2 billion. Included in the acquisition, which has been approved by the Bayer supervisory board, is an extensive portfolio of in vitro diagnostics products for evaluating and monitoring the therapy of numerous diseases. Also included is the systems business, which includes hardware, information technology (IT) networking, and comprehensive equipment service. Not included are the Diabetes Care Division of Bayer and the diagnostic imaging business of Schering.